150 related articles for article (PubMed ID: 21575929)
41. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
Dickinson M; Cherif H; Fenaux P; Mittelman M; Verma A; Portella MSO; Burgess P; Ramos PM; Choi J; Platzbecker U;
Blood; 2018 Dec; 132(25):2629-2638. PubMed ID: 30305280
[TBL] [Abstract][Full Text] [Related]
42. Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway.
Hellström-Lindberg E; Kanter-Lewensohn L; Nichol J; Ost A
Br J Haematol; 1999 Jun; 105(4):966-73. PubMed ID: 10554808
[TBL] [Abstract][Full Text] [Related]
43. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
Quintás-Cardama A; Daver N; Kim H; Dinardo C; Jabbour E; Kadia T; Borthakur G; Pierce S; Shan J; Cardenas-Turanzas M; Cortes J; Ravandi F; Wierda W; Estrov Z; Faderl S; Wei Y; Kantarjian H; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):401-10. PubMed ID: 24875590
[TBL] [Abstract][Full Text] [Related]
44. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
45. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
[TBL] [Abstract][Full Text] [Related]
46. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
47. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
[TBL] [Abstract][Full Text] [Related]
48. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
49. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
50. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Kantarjian HM; Giles FJ; Greenberg PL; Paquette RL; Wang ES; Gabrilove JL; Garcia-Manero G; Hu K; Franklin JL; Berger DP
Blood; 2010 Oct; 116(17):3163-70. PubMed ID: 20631375
[TBL] [Abstract][Full Text] [Related]
51. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
Giagounidis A; Mufti GJ; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Hu K; Woodard P; Yang AS; Kantarjian HM
Cancer; 2014 Jun; 120(12):1838-46. PubMed ID: 24706489
[TBL] [Abstract][Full Text] [Related]
52. Demographic, Hematologic, and Clinical Features of Myelodysplastic Syndrome Patients: Results from the First Polish Myelodysplastic Syndrome Registry.
Mądry K; Machowicz R; Waszczuk-Gajda A; Drozd-Sokołowska J; Hołowiecka BS; Wiater E; Mital A; Obara A; Szmigielska-Kapłon A; Kołkowska-Leśniak A; Sikorska A; Subocz E; Mendrek W; Szczepańska M; Biedroń M; Jachalska A; Wasilewska E; Wojciechowska M; Guzicka-Kazimierczak R; Kopacz A; Katinas K; Kruger W; Dawidowska A; Salamańczuk Z; Zawirska D; Świderska A; Jędrzejczak WW; Dwilewicz-Trojaczek J
Acta Haematol; 2015; 134(2):125-34. PubMed ID: 25925777
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes.
Wimazal F; Germing U; Kundi M; Noesslinger T; Blum S; Geissler P; Baumgartner C; Pfeilstoecker M; Valent P; Sperr WR
Cancer; 2010 May; 116(10):2372-81. PubMed ID: 20209617
[TBL] [Abstract][Full Text] [Related]
54. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
55. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
56. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
57. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.
Wang H; Wang X; Xu X; Lin G
Ann Hematol; 2010 Jun; 89(6):535-44. PubMed ID: 19921190
[TBL] [Abstract][Full Text] [Related]
58. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Waisbren J; Dinner S; Altman J; Frankfurt O; Helenowski I; Gao J; McMahon BJ; Stein BL
Int J Hematol; 2017 Jan; 105(1):44-51. PubMed ID: 27558575
[TBL] [Abstract][Full Text] [Related]
59. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040
[TBL] [Abstract][Full Text] [Related]
60. [Myelodysplastic syndromes. A clinico-biological analysis of 27 cases].
Mereuţă A; Turtureanu-Hanganu E
Rev Med Chir Soc Med Nat Iasi; 1990; 94(1):67-73. PubMed ID: 2075337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]